I think NVS’s action is intended to prevent MS patients from masquerading as CLL patients and thereby procuring ofatumumab at the lower unit price for Arzerra as compared to Kesimpta.
By taking full control of the drug supply for US Arzerra patients, NVS preempts the form of “indication arbitrage” described above.
Market Data 
Markets 
AI
